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Background: Hepatocellular carcinoma (HCC) is prevalent worldwide and early diagnosis of HCC is critical for
effective treatment and optimal prognosis.
Methods: Serum was screened ﬁrst by immunoproteomic analysis for HCC-related tumor associated antigens
(TAAs). Selected TAAs were clinically evaluated retrospectively in patients with HCC, liver cirrhosis, chronic hepa-
titis and healthy controls. Levels of autoantibody to the selected TAAs were measured by protein microarrays con-
taining protein antigens of the candidate TAAs. Analyses were done by using receiver operating characteristics
(ROC) to calculate diagnostic accuracy.
Findings: Twenty-two candidate TAAswere assessed by proteinmicroarray analysis in 914 participants with serum
α-fetoprotein (AFP) available. Twelve candidate TAAs were statistically different in signal intensity between HCC
and controls. Among them, CENPF, HSP60 and IMP-2 showed AUC (area under the curve) values of 0.826, 0.764
and 0.796 respectively for early HCC. The highest prevalence of autoantibody positivity was observed in HCC
cases with BCLC tumor stage A, well-differentiated histology and Child-Pugh grade C. Speciﬁcally, 73.6% or 79.3%
cases of early HCC with negative AFP were positive for autoantibody to CENPF or HSP60.
Interpretation: Tumor-associated autoimmune reactions may be triggered by early stage HCCs. Measurement of
serum autoantibody to TAAs may be complementary to AFP measurements and improve diagnosis of early HCC.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionHepatocellular carcinoma (HCC) is the sixth most common malig-
nancy and the third leading cause of cancer-related death worldwide
(Theise et al., 2014). Nearly half of all new cases of liver cancer
(50.5%) and related deaths (51.4%) are estimated to occur in China
(Theise et al., 2014). HCC accounts for 70–80% of all liver cancers. The
survival rate of patients with HCC after the onset of symptoms ising Friendship Hospital, Capital
na.
, Beijing Institute of Radiation
ang@bmi.ac.cn (S. Wang),
. This is an open access article undergenerally less than one year on the late presentation of HCC at least in
part due to a lack of reliable tools for early diagnosis (Theise et al., 2014).
Ultrasound is recommended as a screening tool for early detection of
HCC. However, ultrasound is not very sensitive and is highly operator
dependent (Poon et al., 2009). Computed tomography (CT) is not
recommended as a screening tool for HCC because of the attendant
radiation exposure (Poon et al., 2009; Lee et al., 2012). One current
focus of HCC research is the development of a blood test to aid the
diagnosis of this disease. The traditional serum biomarker for HCC,
α-fetoprotein (AFP) has been found to have a sensitivity of 41–65%,
and a speciﬁcity of 80–90% when a cut-off value of 20 ng/ml has been
used. The sensitivity was lower when AFP was used to detect early-
stage HCC (Farinati et al., 2006). Many other serologic biomarkers of
HCC are available, including des-gamma carboxyprothrombin (DCP)
and Lens culinaris agglutinin-reactive AFP (AFP-L3) (Bertino et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of research subjects for SERPA analysis and microarray detection.
Variables SERPA analysis (n = 30) Microarray detection (n = 914)
HCC
(n = 10)
Liver cirrhosis
(n = 10)
Healthy control
(n = 10)
HCC
(n = 295)
Liver cirrhosis
(n = 132)
Chronic hepatitis
(n = 119)
Non-liver cancers
(n = 103)
Healthy controls
(n = 265)
AFP (ng/ml) b20 6 8 10 122 116 101 101 265
20–400 4 2 0 119 15 17 2 0
N400 0 0 0 54 1 1 0 0
Age (years) Range 43–65 36–62 28–60 24–88 31–76 25–66 25–90 20–66
(Mean) (52.6) (48.3) (43.5) (56.3) (50.2) (43.2) (64.0) (45.8)
Gender Male 7 7 7 239 101 96 58 166
Female 3 3 3 56 31 23 45 99
HBV/HCV infection HBV+ 10 10 0 260 108 96 1 0
HCV+ 0 0 0 17 15 13 2 0
HBV−/HCV− 0 0 10 18 9a 10a 89b 265
HBsAg Positive 10 10 0 260 108 96 1 0
Negative 0 0 10 35 24 23 91b 265
ALT (U/L) ≤75 8 8 10 255 107 89 – 265
N75 2 2 0 40 25 30 – 0
Child-Pugh A 8 8 – 239 81 – – –
B 2 2 – 42 37 – – –
C 0 0 – 14 11 – – –
Missing 0 0 – 0 3 – – –
BCLC stage A 10 – – 106 – – – –
B 0 – – 135 – – – –
C 0 – – 39 – – – –
D 0 – – 15 – – – –
Tumor differentiation Well 4 – – 32 – – – –
Moderate 6 – – 77 – – – –
Poor 0 – – 37 – – – –
Missing 0 – – 149 – – – –
Tumor size (cm) ≤5 10 – – 109 – – – –
N5 0 – – 184 – – – –
Missing 0 – – 2 – – – –
Vascular invasion/metastasis Yes 0 – – 46 – – – –
No 10 – – 247 – – – –
Missing 0 – – 2 – – – –
HCC, hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer staging system; HBV+:with HBV infection; HCV+:with HCV infection; HBV−/HCV−: without HBV andHCV infection. SERPA: serological proteome analysis. –: data not available.
a Alcoholic.
b 11 non-liver cancer cases miss the data of HBV/HCV infection.
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440 Y. Hong et al. / EBioMedicine 2 (2015) 438–4462012), Dickkopf-1 (DKK1) (Shen et al., 2012), and squamous cell carci-
noma antigen (SCCA) (Zhao et al., 2013). However, these markers are
insufﬁcient for the early diagnosis of HCC (Yau et al., 2013; Stefaniuk
et al., 2010). Therefore, there is an urgent need for the identiﬁcation of
novel diagnostic markers for this purpose.
Recent studies have shown that the abnormal protein release by
tumor cells can elicit humoral immune responses as self-antigen and
are called tumor-associated antigens (TAAs). Unlike autoantibodies in
autoimmune diseases, autoantibodies against the TAAs have been
reported in a wide variety of tumors. Some have been reported to be
present several months to years before manifestations of the clinical
signs of tumor (Tan et al., 2009; Xu et al., 2014; Werner et al., 2015).
Furthermore, magniﬁed signals of the anti-TAA autoantibodies can be
easier to detect than TAAs themselves, suggesting that the measure-
ment of anti-TAA antibodies may have various advantages as immuno-
diagnostic markers (Tan et al., 2009; Lacombe et al., 2014). Therefore,
anti-TAA autoantibodies seem to have great potential value in the
screening and early diagnosis of cancer. Autoantibodies against TAAs
have been reported in patients with HCC, but only by a series of studies
on small cohorts (Yau et al., 2013). Therefore, the potential value of the
anti-TAAs as serumbiomarkers for HCC especially for early stage HCC, is
still unclear.
The aim of the present studywas to use a proteinmicroarray system
for high throughput analysis (Bruix et al., 2005) to screen for
autoantibody-based serum markers for early HCC, and to evaluate the
value and timing of those autoantibodies in the early diagnosis of HCC.
2. Material and Methods
2.1. Study Population
For screening of speciﬁc TAAs for earlyHCC, total protein from frozen
tissues of ten cases of HCC was extracted as an antigen library for
serological proteome analysis (SERPA). The tumor samples were
obtained from patients with hepatitis B virus (HBV)-related HCC with
Barcelona Clinic Liver Cancer staging system (BCLC) stage A. The
patients underwent surgical treatment at the Beijing You-An Hospital
from 2011 to 2012. There were 7 men and 3 women, aged 42–62 years
with a median age of 51.5 years. Serum samples for SERPA were also
obtained from10 cases of HBV-relatedHCCwith BCLC stage A. The demo-
graphics were 7men and 3women, aged 43–65 years with amedian age
of 52.6 years. Other sera from 10 HBV-related cirrhosis patients without
HCC, and 10 healthy volunteers were used as controls.
For clinical validation, a total of 914 serum samples were applied,
including 295 cases of HCC, 132 cases of liver cirrhosis, 119 cases of
chronic hepatitis, 103 cases of other cancers (23 colon cancer, 31 rectal
cancer, 30 gastric cancer and 19 non-gastrointestinal tumor), and 265
healthy controls. Clinical characteristics of the samples are shown in
Table 1 and supplementary Tables 1 and 2. All the samples had AFP levels
measured with a commercially available electrochemiluminescence im-
munoassay kit (Roche, USA). Samples with an AFP value of more than
20 ng/ml were deﬁned as AFP positive. The patients were retrospectively
recruited during 2010–2013 from the Liver Research Center, Depart-
ments of Oncology, and General Surgery, Beijing Friendship Hospital,
Capital Medical University, Department of Minimally Invasive Interven-
tional Radiology, Beijing Youan Hospital, Capital Medical University and
the Department of Hepatopancreatobiliary and SplenicMedicine, Afﬁliat-
ed Hospital of Medical College of Chinese People's Armed Police Force.
HCC diagnosis was based on ultrasound, CT, or Magnetic Resonance Im-
aging (MRI) characteristics and biochemistry (AFP serology and liver
function enzymes), according to the American Association for the Study
of Liver Diseases guidelines (Bruix et al., 2005). Early-stage HCC was de-
ﬁned according to the BCLC stage 0+ A (Llovet et al., 2008). Diagnosis of
chronic hepatitis B included thepresence ofHBsAgmore than sixmonths,
HBV DNA concentrations higher than 103 copies/ml and serum alanine
aminotransferase elevation, according to the guidelines of preventionand treatment of chronic HBV infection (Lok andMcMahon, 2009). Diag-
nosis of chronic hepatitis Cwas based on positivity for anti-HCV antibody
along with HCV RNA (N500 IU/ml) in patients with signs of chronic hep-
atitis. Alcoholic hepatitis was deﬁned by the history of alcohol abuse
more than 5 years (alcohol consumption for male≥40 g/day and female
≥20 g/day) or alcohol consumption≥80 g/day within 2 weeks, elevated
ALT, AST, GGT and AST/ALT N 2without evidence of liver dysfunction and
HBV/HCV infection. Diagnosis of liver cirrhosis shouldmeet at least one of
the following three criteria: (1) Histologically conﬁrmed of cirrhosis
(Metavir F4 or Ishak 5/6); (2) clinically presentence of liver dysfunction
(albumin b35.0 g/l, or International Normalized Ratio (INR) N1.3) and
portal hypertension (endoscopy showing esophageal varices, or imaging
showing liver surface nodularity, splenomegaly or hypersplenism);
(3) chronic liver disease with development of ascites, variceal bleeding
or encephalopathy. Non-liver cancer patients were pre-operative
patients who had no history of liver disease. The healthy controls were
eligible blood donors with normal liver biochemistry, no history of liver
disease and no malignant disease. Patients with autoimmune liver
disease such as autoimmune hepatitis, primary biliary cirrhosis, as well
as other autoimmune diseases such as diabetes, rheumatoid arthritis,
and systemic lupus erythematosus were excluded from the study.
All the sampleswere stored at−80 °C until testing. The study proto-
col was approved by the Clinical Research Ethics Committee of Beijing
Friendship Hospital, Capital Medical University. All participants provid-
ed their written informed consent to participate in this study.
2.2. SERPA Analysis for the Screening of HCC-related TAAs
Total protein from tumor tissue was extracted as described
previously (Wang et al., 2014). Brieﬂy, frozen tissue was lysed in
5 μl lysis buffer (7 mol/L urea, 2 mol/L thiourea, 4% 3-[(3-
cholamidopropyl)dimethylamino]-1-propanesulfonate (CHAPS),
1% dithiothreitol (DTT), 2% immobilized pH gradient (IPG) buffer
(pH 3–10), protease inhibitor cocktail) per mg tissue, and clariﬁed by
centrifugation. After measurement of protein concentration with a
2-D Quant kit (GE Healthcare), the extracted protein was puriﬁed
with a 2-D Clean-up kit (GE Healthcare). Equal parts of total proteins
extracted from tumor tissue of HCC cases were mixed before use.
SERPA analyses were performed as described previously (Li et al.,
2008). Brieﬂy, the ﬁrst dimensional isoelectric focusing (IEF) was
performed on pre-cast 18 cm immobilized pH 3–10 gradient (IPG)
strips (GE Healthcare) with a total of 800 μg protein. Following IEF,
the second dimensional sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed and followed by Western
Blot analysis with serum samples at 1:100 dilution as the source of
primary antibodies. After incubation with horseradish peroxidase
(HRP) conjugated goat anti-human IgG (Invitrogen) at 1:5000 dilution,
immunoreactive spots were detected using the ECL kit (Millipore)
according to the manufacturer's instructions. The proteomic proﬁle of
proteins from the HCC tissuewas used as a referencemap for spot anal-
ysis. Spots on immunoblotting maps were matched to the reference
map, and those detected in early HCC serum but not in liver cirrhotic
or normal sera were excised for protein identiﬁcation. Matrix-assisted
laser desorption/ionization-time-of-ﬂight (MALDI-TOF) mass spec-
trometer (Bruker Daltonics, Bremen, Germany) was used for identiﬁca-
tion of the selected proteins. Mascot (Matrix Science, London, UK) was
used for protein identiﬁcation by searching the peak lists against the
International Protein Index (IPI) Human database. A protein score
with a p-value less than 0.05 was considered signiﬁcant.
2.3. ProteinMicroarray Analysis for the Clinical Validation of Screened TAAs
Full length or fragments of recombinant proteins for selected TAAs
which were available for enzyme-linked immunosorbent assay (ELISA)
were purchased whenever possible. For two TAAs i.e. apoptosis-
inducing factor (AIF) and heterogeneous nuclear ribonucleoprotein
441Y. Hong et al. / EBioMedicine 2 (2015) 438–446(hnRNP) A2, the full length recombinant proteins were prepared as
described previously (Li et al., 2008).
The preparation of protein microarray and the microarray detection
of serum samples were performed according to our previous study (Li
et al., 2008). Brieﬂy, the screened TAA proteins were diluted with an
optimized individual concentration and robotically attached in ordered
arrays on aldehyde-activated glass slides by a computer-controlled
microchip spotting instrument (Cartesian Pixsys 3000). Human IgG
(Sigma, St. Louis, MO) was used as a positive control and an internal
standard for calibration of signal intensity of each test, while bovine
serum albumin (Sigma) and sample liquid were used as negative con-
trols. Microarray detection was performed with serum samples at 1:5
dilution. After incubation with rabbit anti-human IgG conjugated to
HRP(sigma) at 1:8000 dilution, immunoreactive spots were detected
using a chemiluminescent solution (Millipore). The signal intensities
of the spots and background values were measured using array vision
7.0 (array vision, USA).
2.4. Western Blots and Immunohistochemistry Analysis for CENPF
For the analysis of levels of autoantibody to centromere protein F
(CENPF), a recombinant N-terminal 120–220 amino acid fragment of
CENPF protein with an N-terminal glutathione S-transferase (GST) tag
was prepared (data not shown) as the antigen forWestern Blot analysis,
as described in our previous studies (Wang et al., 2014; Li et al., 2008).
Brieﬂy, Western Blot analysis was performed with antibody against
GST (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:4000 dilution
or serum samples at 1:250 dilution as primary antibodies. AfterFig. 1.Microarray detection and validation of autoantibodies in liver cirrhosis, chronic hepatitis
array for high-throughput clinical validation. (a) Design of the protein microarray. ● IgG, 1. I
ALDH1A1, 10. PDIA1, 11. ENO1, 12. ANXA4, 13. CENPF, 14. SBP1, 15. ACY1, 16. hnRNP A2, 1
(0.01 M PBS, pH 7.0); (b) scan images of a representative antigen array. B. Microarray detectio
serum (b), chronic hepatitis serum (c), serum from other cancers (d), or normal serum (e). C.
protein microarray. (a) RepresentativeWestern Blot with recombinant proteins CENPF showin
teinmicroarray. The lanewith “+” indicates antibody against GST used as a positive control; lane
462 and 635, respectivelywith signal intensities of 1025, 5068 and 20018 detected by the protei
of autoantibody against CENPF in HCC sera detected by the protein microarray. Lane 1: the norincubation with HRP-conjugated goat anti-human IgG (Invitrogen) at
1:5000 dilution, immunoreactive spots were detected using the ECL
kit (Millipore) according to the manufacturer's instructions.
For immunohistochemistry (IHC) analysis of CENPF, sections (4 μm
thick) were cut, and after deparafﬁnization of the slides, endogenous
peroxidase activity was blocked with 0.3% H2O2 in methanol for
30 min. Immunohistochemical staining was performed using anti-
human CENPF antibody (diluted 1:100, Abcam) at 37 °C for 1 h, and
visualization of antigen–antibody reactions was achieved with 3,30-di-
aminobenzidine (Vector SK-4100). Tissue structures were visualized by
counterstaining with hematoxylin. The slides were examined separately
by two independent pathologists without any prior knowledge of the
patient's clinical and pathological parameters.2.5. Statistical Analysis
Statistical analysis was performed with SPSS for Windows (version
19.0) and MedCalc (version 10.4.7.0). Differences between two
independent groups were tested with the ANOVA. Receiver operating
characteristic (ROC) curves were constructed to assess sensitivity,
speciﬁcity, and respective areas under the curves (AUCs) with 95% CI
to evaluate the diagnostic value of the serum markers. The optimum
cutoff values for diagnosis were determined by calculating the Youden
index, and the corresponding signal intensity numberwas set as a cutoff
value for positivity of individual autoantibodies to TAAs. The correla-
tions between autoantibody positivity in serum and clinicopathological
characteristicswere analyzed using the chi-squared (χ2) testwith Yate's, HCC, other cancers and normal serum. A. Schematic representation of the protein micro-
GKC, 2. HSP60, 3. A1AT, 4. IMP-2, 5. FIBB, 6. HSPA6, 7. ATPB, 8. Bovine serum albumin, 9.
7. K2C1, 18. AIF, 19. CRT, 20. RGN, 21. PRDX3, 22. HINT1, 23. TBB4B, 24. Sample liquid
n of serum sample. Individual arrays were incubated with HCC serum (a), liver cirrhosis
Western Blots showing a pattern of antibody titers to CENPF in HCC sera detected by the
g reactivity of HCC sera with various levels of auto-antibody to CENPF detected by the pro-
1, a normal human serumused as negative control; lanes 2–4, threeHCCpositive sera 569,
nmicroarray;M. EasySeeWesternMarker (TransGenBiotech, Beijing). (b) Signal intensity
mal serum sample; lanes 2–4: the three HCC positive sera 569, 462 and 635.
Fig. 2. ROC curves of the 22 TAAs indiscriminatingbetweenHCCand controls and representative scatter diagramof signal intensity of CENPF, HSP60 and IMP-2. Upper panel: ROC curve for
the 22 TAAs. A. 12 of the 22 TAAs with p-values b 0.05. B. 10 of the 22 TAAs with p-values N 0.05. Lower panel, scatter diagrams: signal intensity in early-HCC, HCC, LC, CH, HC and other
cancers. C. CENPF. D.HSP60. E. IMP-2. Black horizontal lines indicatemeans, and error bars are SEs. ROC, receiver operating characteristic. HCC, hepatocellular carcinoma; LC, liver cirrhosis;
CH, chronic hepatitis; HC, healthy controls.
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statistical signiﬁcance.
3. Results
Using an antigen library of amixture of total proteins extracted from
tumor tissue of 10 cases of early HBV related-HCC, SERPA analysis was
performed for the screening of HCC-related TAAs. Mixtures of serum
samples of ten early HBV-related HCC cases, ten HBV-related cirrhosis
cases, and ten healthy controls were used as primary antibody for
Western Blot analyses. Supplementary Fig. 1A shows a representative
Coomassie blue-stained 2-DE. Different patterns of reactivity were ob-
tained by probing with HCC serum, liver cirrhosis serum, and normal
control serum, and representative immunoreactive patterns with HCC,Table 2
Diagnostic value of autoantibodies to CENPF, HSP60 and IMP-2 for HCC or early-HCC.a
aAb Case number
HCC/LC/CH/HC
AUC value 95% CI Cuto
CENPF aAb
HCC 291/105/83/200 0.816 0.785 to 0.844 N11
Early-HCC 106/105/83/200 0.826 0.790 to 0.859 N11
HSP60 aAb
HCC 291/91/85/201 0.750 0.715 to 0.783 N37
Early-HCC 106/91/85/201 0.764 0.723 to 0.801 N37
IMP-2 aAb
HCC 92/99/91/65 0.708 0.656 to 0.756 N6
Early-HCC 38/99/91/65 0.796 0.746 to 0.841 N6
a Control: liver cirrhosis + chronic hepatitis + healthy controls; aAb: autoantibody; AUC, ar
dictive value; HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; HC, healiver cirrhosis and normal control serum are shown in Supplementary
Fig. 1B–D. By comparing and matching the antigenic protein proﬁle of
each 2-D immunoblot on the original 2-DE, we identiﬁed 18 protein
spots that were frequently recognized by HCC serum, but not by
serum from liver cirrhosis and normal controls (Supplementary
Fig. 1A). By MALDI-TOF mass spectrometry analysis, the 18 immunore-
active proteins which exhibited different frequencies of recognition
were identiﬁed (Supplementary Table 3).
A total of 22 TAAs were used to make protein microarrays for high
throughput clinical validation, including the 18 TAAs screened by the
present study. For comparison of performance of the TAAs, we also
included in the protein microarray two TAAs reported by other studies:
insulin-like growth factor 2 mRNA-binding protein 2 (IMP-2) (Zhang
and Chan, 2002) and calreticulin (CRT) (Pekarikova et al., 2010), asff value Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
52 75.3 73.7 68.2 79.9
52 76.2 73.7 44.0 92.0
12 77.7 62.2 61.4 78.3
12 78.1 62.2 36.6 91.1
40 69.2 65.1 37.8 87.4
40 81.6 65.1 25.8 96.0
ea under curve; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative pre-
lthy controls.
Table 3
Correlation between the prevalence of autoantibody positivity and clinicopathological parameters in HCC.
Parameters Prevalence of autoantibody positivity
CENPF aAb p value HSP60 aAb p value IMP-2 aAb p value
Sex
Male 180/236 (76.3%) 0.407 185/236 (78.4%) 0.538 51/75 (68.0%) 0.794
Female 39/55 (71.0%) 41/55 (74.6%) 11/17 (64.7%)
Age
b50 66/78 (84.6%)a 0.025 158/168 (94.1%)a 0.000 20/27 (74.1%) 0.378
≥50 153/213 (71.8%) 68/123 (55.3%) 42/65 (64.6%)
HBV infection
HBV (+) 198/260 (76.2%) 0.305 200/260 (76.9%) 0.380 57/83 (68.7%) 0.672
HBV (−) 21/31 (67.7%) 26/31 (8.39%) 5/9 (55.6%)
Child-Pugh
A 172/237 (72.6%)a 0.046 180/237 (76.0%) 0.189 48/68 (70.6%) 0.272
B 34/40 (87.0%) 33/40 (85.2%) 8/16 (50.0%)
C 13/14 (92.9%) 13/14 (92.9%) 6/8 (75.0%)
BCLC stage
A 80/105 (76.2%) 0.782 82/105 (78.1%) 0.894 28/38 (73.7%) 0.280
B & C & D 139/186 (74.7%) 144/186 (77.4%) 34/54 (63.0%)
Histology
Well differentiated 31/32 (96.7%)a 0.003 27/32 (84.4%) 0.109 8/11 (72.7%) 1.000
Moderately/poorly differentiated 82/114 (71.9%) 80/114 (70.2%) 21/31 (67.7%)
AFP
≤20 ng/ml 89/122 (73.0%) 0.173 101/122 (82.8%) 0.187 36/53 (67.9%) 0.768
20–400 ng/ml 84/115 (73.0%) 84/115 (73.0%) 24/37 (64.9%)
N400 ng/ml 46/54 (85.2%) 41/54 (7.59%) 12/16 (75.0%)
Tumor size
≤5 cm 83/109 (76.2%) 0.786 85/109 (78.0%) 0.920 28/38 (73.7%) 0.280
N5 cm 136/182 (74.7%) 141/182 (77.5%) 34/54 (63.0%)
Vascular invasion or metastasis
Yes 32/46 (69.6%) 0.330 36/46 (78.3%) 0.916 5/7 (71.4%) 1.000
No 187/245 (76.3%) 190/245 (77.6%) 57/86 (66.3%)
a With statistic signiﬁcance. aAb: autoantibody.
443Y. Hong et al. / EBioMedicine 2 (2015) 438–446well as two TAAs identiﬁed by our previous study: AIF and hnRNP A2 (Li
et al., 2008). The recombinant proteins of the 22 TAAs applied for prep-
aration of the protein microarray are shown in Supplementary Table 4.
A schematic representation of antigen array, and the representative
scan images of the proteinmicroarray are shown in Fig. 1A and B.West-
ern Blot analysis of threeHCC serawith various levels of autoantibody to
CENPF identiﬁed by the microarray detection showed consistent serum
levels of autoantibody to CENPF conﬁrming the results obtained by the
microarray detection (Fig. 1C).
After microarray detection with the 914 serum samples, ROC curves
were made for all 22 TAAs based on the individual signal intensity, and
the results showed CENPF, 60 kDa heat shock protein (HSP60), IMP-2,
protein disulﬁde-isomerase (PDIA1), aminoacylase-1 (ACY1), alpha-
enolase (ENO1), annexin A4 (ANXA4), Ig kappa chain C region (IGKC),
regucalcin (RGN), keratin, type II cytoskeletal 1 (K2C1), heat shock
70 kDa protein 6 (HSPA6) and CRT were signiﬁcantly different
(p b 0.05) between HCC and all controls (Fig. 2A–B, Supplementary
Table 5). Among them, the three TAAs, CENPF, HSP60 and IMP-2
showed better diagnostic value in HCC or early HCC, with AUC (area
under the curve) values of 0.816, 0.750 and 0.708, or 0.826, 0.764 andTable 4
Comparison of diagnostic value of CENPF or HSP60 autoantibody with AFP for Early-HCC.a
aAb &AFP Cases AUC
value
CENPF aAb Early-HCC vs LC + HC + CH 0.826
HSP60 aAb 0.764
AFP 0.749
CENPF aAb Early-HCC vs LC 0.660
HSP60 aAb 0.690
AFP 0.675
CENPF aAb Early-HCC vs LC + CH 0.727
HSP60 aAb 0.689
AFP 0.695
a aAb: autoantibody; AUC, area under curve; CI, conﬁdence interval; PPV, positive predictive v
chronic hepatitis; HC, healthy controls. The diagnostic cutoff values of AFP and aAb to CENPF a0.796 respectively (Table 2), as well as signiﬁcantly different signal in-
tensities among HCC, liver cirrhosis, chronic hepatitis, healthy control,
and other cancers (Fig. 2C–E). Comparison of prevalence of autoantibody
positivity to CENPF and HSP60 between HCC and control cases showed
signiﬁcant difference in the number of case with autoantibody positivity
to CENPF andHSP60 between HCC and liver cirrhosis or chronic hepatitis
or healthy control (Supplementary Table 6). Analysis of the clinicopatho-
logical association showed that the prevalence of autoantibody positivity
to CENPF and HSP60was higher in HCC patients whowere younger than
50 (p b 0.05), and the prevalence of autoantibody positivity to CENPFwas
higher in patients with well-differentiated HCC or with Child-Pugh grade
C (p b 0.05, Table 3). Notably, for all three TAAs, CENPF, HSP60 and IMP-2,
the highest prevalence of autoantibody positivity was observed in HCC
cases with tumor stage BCLC A, well-differentiated histology and Child-
Pugh grade C (Table 3), suggesting that the TAAs may be a good marker
for surveillance and diagnosis of early HCC.
We compared only the diagnostic value of CENPF and HSP60 for
early HCC with AFP, because the number of cases with results of
IMP-2 autoantibody was insufﬁcient. In contrast with total HCC, better
performance of autoantibody to CENPF and HSP60 than AFP was95% CI Sensitivity
(%)
Speciﬁcity
(%)
0.790 to 0.859 76.2 73.7
0.723 to 0.801 78.1 62.2
0.708 to 0.786 49.5 93.3
0.592 to 0.724 76.2 37.1
0.620 to 0.754 78.1 50.6
0.607 to 0.738 49.5 87.6
0.672 to 0.777 76.2 53.7
0.631 to 0.742 78.1 46.0
0.638 to 0.747 49.5 86.2
alue;NPV, negative predictive value;HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH,
nd HSP60 were 20 ng/ml, and signal intensity of 1152 and 3712 respectively.
Fig. 3. Comparison of the diagnostic value among autoantibodies to CENPF, AFP and combined autoantibody to CENPF and AFP for HCC or early HCC. Upper panel: ROC curve for autoan-
tibodies to CENPF, AFP and combined autoantibody to CENPF and AFP to distinguish HCC (A) or early HCC (B) from controls (LC+CH+HC). Lower panel: comparison of positivity for the
autoantibodies to CENPF, AFP and combined autoantibody to CENPF and AFP in HCC (C) or early-HCC (D). ROC, receiver operating characteristic. HCC, hepatocellular carcinoma; LC, liver
cirrhosis; CH, chronic hepatitis; HC, healthy controls; aAb: autoantibody.
444 Y. Hong et al. / EBioMedicine 2 (2015) 438–446shownwhen comparing early-HCC and all controls (Table 4, Fig. 3A–D),
with AUC values of 0.826, 0.764 and 0.749, respectively. However, for
distinguishing early-HCC from liver cirrhosis or liver cirrhosis plus
chronic hepatitis, the AUC values of autoantibody to CENPF or HSP60
were similar with that of AFP (Table 4). The prevalence of autoantibody
positivity to CENPF and HSP60 was signiﬁcantly higher than that of AFP
positivity in HCCs with tumor stage of BCLC A (p b 0.001) (Supplemen-
tary Table 7), suggesting a higher diagnostic value of autoantibody for
early HCC compared with the AFP. Speciﬁcally, 73.6% and 79.3% cases
of early HCC with AFP negativity were seropositive for autoantibody to
CENPF or HSP60, with AUC values of 0.828 and 0.779, respectively
(Table 5, Fig. 3D). These data indicated that the TAAs could be used as
a complement for AFP in the diagnosis of AFP-negative early HCC toTable 5
The diagnostic value of autoantibody to CENPF and HSP60 in AFP negative early-HCC.a
aAb Cases AUC value 95% CI
CENPF aAb Early-HCC vs LC + HC + CH 0.828 0.790 to 0.8
Early-HCC vs LC 0.659 0.579 to 0.7
Early-HCC vs LC + CH 0.727 0.666 to 0.7
HSP60 aAb Early-HCC vs LC + HC + CH 0.779 0.737 to 0.8
Early-HCC vs LC 0.706 0.624 to 0.7
Early-HCC vs LC + CH 0.706 0.643 to 0.7
a aAb: autoantibody; AUC, area under curve; CI, conﬁdence interval; PPV, positive predictive
HSP60 were signal intensity of 1152 and 3712 respectively. HCC, hepatocellular carcinoma; LCimprove the detection rate. Combined autoantibody to CENPF with
AFP improved the ability to distinguish HCC from all controls, with the
AUC value of 0.894, or with sensitivity of 88.7% and speciﬁcity of 68.8%
in the diagnosis of HCC (Fig. 3A, C); and with AUC of 0.882, or with sen-
sitivity of 86.7% and speciﬁcity of 68.8% in the diagnosis of HCC at an
early stage (Fig. 3B, D).
To explore the possible mechanism underlying the occurrence of
autoantibody to CENPF in HCC, we analyzed the expression level and
cellular localization of CENPF in HCCwith various levels of autoantibody
to CENPF. IHC analysis was performed on ﬁveHCC caseswith high levels
of serum autoantibody to CENPF (signal intensity more than 4000) and
ﬁve HCC cases with negative serum autoantibody to CENPF (signal
intensity less than 500). The results showed that in all HCC casesSensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
62 73.6 73.7 27.7 95.3
32 73.6 37.1 37.1 73.6
82 73.6 53.7 31.0 87.8
17 79.3 62.2 22.8 95.5
79 79.3 50.6 48.3 80.7
65 79.3 46.0 30.7 88.0
value; NPV, negative predictive value. The diagnostic cutoff values of aAb to CENPF and
, liver cirrhosis; CH, chronic hepatitis.
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overexpression of CENPF was observed in tumor tissue of all HCC
cases with high levels of serum autoantibody to CENPF, while low or
no CENPF expression was observed in the tumor tissue of all HCC
cases with low levels of serum autoantibody to CENPF (Supplementary
Fig. 2). The data suggest that the elevated CENPF autoantibody may
have resulted from overexpression of CENPF protein.
4. Discussion
Although there has been an increase in the number of reports of
TAAs in various types of tumor including HCC (Yau et al., 2013;
Werner et al., 2015; Lacombe et al., 2014), the potential value of
autoantibodies in the early diagnosis of HCC remains unclear. The
major concern is that the majority of studies initially screen small
sample sizes without validation by large-scale samples. In the present
study, using high throughput screening and clinical validation, we
reported here a series of TAAs, which might be valuable markers for
early detection of HCC.
Simultaneous clinical validation of dozens of candidate bio-markers
with large-scale samples is extremely difﬁcult. It is almost impossible to
conduct large-scale screening and validation studies for speciﬁc tumor
markers. The traditional techniques such as ELISA, Western Blot analy-
sis, and radioimmunoassays which require relatively large quantities
of antigen and patient samples are of limited use when performing
large-scale clinical validations (Robinson et al., 2002), especially when
performing numerous simultaneous validations. In the present study,
we believe that we have identiﬁed for the ﬁrst time, a series of TAAs
in HCC using SERPA analysis with total protein extracted from tumor
tissue as antigen library. We have also validated the diagnostic value
of candidate TAAs compared with that of AFP in a large cohort of early
HCC. Twelve of the 22 candidate TAAs were identiﬁed with signiﬁcance
differences between HCC and controls. Five of the 12 screened TAAs
have been reported previously in HCC or other cancers, including
IMP-2 (Zhang and Chan, 2002), CRT (Pekarikova et al., 2010), ENO1
(Takashima et al., 2005), CENPF (Liu et al., 2012), and HSP60 (He
et al., 2007), whereas the other seven TAAs in HCC are reported here
for the ﬁrst time, to the best of our knowledge. Three TAAs, CENPF,
HSP60, and IMP-2 showed promise for diagnosis of HCC and early
HCC, with an AUC value of more than 0.7, a recognized standard for bio-
markers, which have a promising diagnostic value in general (Shen
et al., 2012). However, the fact that the majority of screened TAAs
were identiﬁed with low value for diagnosis suggests the importance
of high throughput clinical evaluation of the candidate TAAs.
As an essential nuclear protein associated with the centromere–
kinetochore complex, CENPF plays a critical role in chromosome segre-
gation duringmitosis (Dai et al., 2013). Researchers have demonstrated
that CENPF is overexpressed in a wide variety of human malignancies
including HCC, and CENPF is an independent prognostic factor for HCC
(Dai et al., 2013). A recent study has also reported detection of autoan-
tibodies to CENPF in HCC by screening a T7 cDNA expression library (Liu
et al., 2012). HSP60 is a chaperone with essential functions for cell
physiology and survival, and has been reported to be involved in the
pathogenesis of a number of cancers and some autoimmune disorders
(Calderwood et al., 2012). HSP60 has also been shown to be present in
a broad spectrum of cancers in both tissue and serum (Hamelin et al.,
2011), and has been identiﬁed as a TAA in breast cancer, colorectal
cancer and ovarian cancer (He et al., 2007; Bodzek et al., 2014). The
autoantibodies to CENPF and HSP60 were also identiﬁed in the present
study, but unlike the results of previous studies, their diagnostic value
for early HCC was demonstrated through high throughput clinical
evaluation. IMP-2 and CRT have been reported as TAAs of HCC and
many other types of cancer by several studies (Zhang and Chan, 2002;
Pekarikova et al., 2010), but not identiﬁed in the present study.
However, the diagnostic value of IMP-2 for HCC was conﬁrmed in the
present study. Although there was a signiﬁcant difference betweenautoantibody levels to CRT in HCC compared to controls, the AUC
value was only 0.566, suggesting low diagnostic value for autoantibody
to CRT. Another Ca-regulating protein, RGN for Ca-binding, also showed
a statistically signiﬁcant difference between HCC and controls, but with
an AUC value of only 0.582 suggesting a similar diagnostic value as CRT.
So far, there has been less analysis concerning the clinicopathologi-
cal association and comparison with AFP in the studies concerning
anti-TAA autoantibodies in cancer (Yau et al., 2013; Werner et al.,
2015; Lacombe et al., 2014). In the present study, clinicopathological
analysis demonstrated that three TAAs, CENPF, HSP60 and IMP-2 had
the highest prevalence of autoantibody positivity in HCC cases with
tumor stage BCLC A, well-differentiated histology and Child-Pugh
grade C. Therefore, the clinicopathological analysis in the present
study implies that TAAs may have value in surveillance and diagnosis
of early HCC. To date, AFP is still the main serum biomarker for HCC
surveillance. However, AFP does not yield satisfactory results in the
early diagnosis of HCC, particularly AFP-negative HCC. It has been
reported that in small hepatic tumors, AFP expression is lower, whereas
AFP expression is high in large tumors (Zhao et al., 2013). The AFP level
was approximately correlated with tumor size; 80% of small HCCs did
not have increased levels of AFP. The sensitivity of AFP was 52% when
the tumor diameter was N3 cm, but decreased to 25% for tumors
b3 cm (Farinati et al., 2006; Zhao et al., 2013). The present study
showed that several anti-TAA autoantibodies were better than AFP for
the diagnosis of early HCC when analyzed with all controls, whereas
the efﬁcacy of the TAAs was similar to AFP in distinguishing early HCC
from liver cirrhosis. HCCs occur generally from liver cirrhosis. Although
the speciﬁcity of CENPF (37.1%) or HSP60 (50.6%) autoantibody seemed
to be relatively low for the discrimination of HCC from liver cirrhosis,
with autoantibody positivity to CENPF or HSP60 in 73.6% or 79.3% of
AFP negative early HCC cases (see Table 5), the TAAs could be used as
a complement for AFP in the diagnosis of AFP-negative early HCC to im-
prove the detection rate of early HCC, and the combined autoantibody
to TAAs with AFP could be helpful for the detection of AFP-negative
early HCC. It is worthy to note that the prevalence of the above TAAs
in LC patients was relatively high, suggesting their potential value in
the detection of LC, and should be investigated further.
The generation of autoantibodies to TAAs is not fully understood.
TAA proteins are most likely either mutated, overexpressed, post-
translationallymodiﬁed,misfolded, aberrantly cleaved, or aberrantly lo-
calized in tumor cells (Casiano et al., 2006). It has been reported that
HSP60 localizes mainly in the mitochondria, but in tumor cells it is
also found in the cytoplasm and the cell membrane, leading to activa-
tion of autoimmune reactions (Cappello et al., 2013). In one recent
study on breast cancer with serum anti-HSP60 autoantibody, it was
demonstrated that the level of expression of HSP60 was signiﬁcantly
higher in tumor tissues suggesting that overexpression of HSP60 may
be at least one of the mechanisms of developing immunogenicity
against this protein in breast cancer patients (Cappello et al., 2013).
Similarly, the present study also showed that the high titer of CENPF
autoantibody in HCC serum may result from an auto-immune reaction
in response to overexpression of CENPF, and may constitute one of the
mechanisms for the generation of autoantibody to CENPF.
One limitation of our study is that the majority of sera were from
patients with HBV-related disease and from China. Although HCV infec-
tions, aswell as alcohol abuse are important causes of HCC, the effects of
these factors were not studied. However, we plan to study the contribu-
tions of these factors in the future. Due to lack of availability of IMP-2
protein, IMP-2 was only studied in a small number of samples. Studies
with more samples are needed. In addition, it is important to evaluate
the data of TAAs before and after HCC occurrence, as well as before
and after therapy. We plan to conduct another follow-up research in
the future to evaluate further the efﬁcacy of TAAs before and after
HCC occurrence and the data of TAAs before and after therapy, as well
as the evaluation for the accuracy of cut-off value of the TAAs by another
independent cohort.
446 Y. Hong et al. / EBioMedicine 2 (2015) 438–446In conclusion, our data showed that autoantibodies against TAAs
may be useful in the detection of HCC at early stages, and could be
complementary to AFP as a screening test for HCC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.03.010.
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